- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05293522
A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.
A Phase 2a, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.
Study Overview
Detailed Description
Facial paralysis can be a consequence of traumatic facial nerve injury, iatrogenic causes, malignancy, congenital syndromes, and viral infections. Prolonged paralysis can result in ocular complications, articulation difficulties, impaired feeding, and difficulty in conveying emotion through expressive movement. The current treatment for permanent facial paralysis is facial reanimation surgery, which encompasses a broad range of procedures that restore form and function to the paralyzed face.
The importance of understanding the health utility of facial paralysis and the value of facial reanimation surgery increases. PEG-fusion is a promising therapy for patients that have or will have nerve conditions or injuries resulting in facial palsy that can be addressed surgically. Patients that have clinical evidence of facial paralysis requiring facial nerve repair from conditions or interventions that have or may result in paralysis will be evaluated for participation. The primary objective is to assess the safety of NTX-001 across 12 months following the nerve repair. The study will measure improvement in Facial Grading System (FG) for efficacy. Additionally, measures will include an EMG evaluation for assessment of nerve function intraoperatively, image-based automatic facial landmark analysis, improvement in Facial Clinimetric Evaluation Scale score, and Patient Global Impression of Change Response (PGIC).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Vicki J Abbas, BSN RN
- Phone Number: 303-263-4646
- Email: vicki.abbas@neuraptive.com
Study Contact Backup
- Name: Seth Schulman, MD
- Phone Number: 617-416-4520
- Email: seth.schulman@neuraptive.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- University of Indiana
-
-
Missouri
-
Saint Louis, Missouri, United States, 63130
- Washington University
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering
-
-
North Carolina
-
Durham, North Carolina, United States, 27710-1000
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Methodist
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The subject has clinical evidence of facial paralysis requiring facial nerve repair from conditions or interventions that have or may result in paralysis.
Exclusion Criteria:
Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
Subjects requiring repair of the intracranial portion of the facial nerve. Subjects requiring repair involving an allograft or conduit except for procedures that require grafting of the other nerve branches when repairing the main facial nerve.
Subjects with Bell's palsy that have signs of spontaneous recovery by 12 months.
Subjects who, in the judgment of the investigator, are not likely to demonstrate meaningful recovery within 6 weeks due to significant facial muscle atrophy.
Subjects on chronic corticosteroid therapy within 14 days of repair.
The subject has documented history or clinical signs of:
Clinically significant neuropathy from any cause i.e., medications, chemotherapy, diabetes; Clinically significant systemic neuromuscular disease; Clinically significant local or systemic neurological deficit from other than the condition under study such as stroke; Or other treatments are known to affect the growth and/or physiology of the neural and vascular system with the exception of radiation therapy; The subject has a known allergy to polyethylene glycol (PEG) or human-grade silicone.
The subject is not able to strictly adhere to the rules of the current clinical protocol, e.g., significant mental health issues, homelessness, incarceration, intellectually or developmentally challenged without proper legal representation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NTX-001
Solution #1, Solution #2 Active, Solution #3
|
2 solutions plus a delivery device; one time use surgical product
|
No Intervention: Standard of Care
Standard neurorrhaphy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events for Safety
Time Frame: Adverse events will be assessed and recorded from start of study through 48 weeks or approximately 1 year..
|
Measuring the safety of NTX-001 following the nerve repair based on the number of reported adverse events.
|
Adverse events will be assessed and recorded from start of study through 48 weeks or approximately 1 year..
|
Sunnybrook Facial Grading System
Time Frame: From screening visit, and at weeks 6, 12, 24, 36, and 48.
|
Change in Sunnybrook Facial Grading score from baseline as compared to Week 6;
|
From screening visit, and at weeks 6, 12, 24, 36, and 48.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative EMG
Time Frame: Once in the operating room.
|
Electromyography (EMG) measures amplitude and duration of facial motor unit action potentials which reflects in the number of innervated muscle fibers.
This may demonstrate if reinnervation or nerve conduction has been restored in the operating room.
|
Once in the operating room.
|
Image-based automatic facial landmark identification system
Time Frame: From screening visit, and at weeks 1, 6, 12, 24, 36, and 48.
|
Image analysis automatically identifies facial landmarks and uses the position of those landmarks to estimate facial symmetry and/or evaluate facial neuromuscular diseases.
|
From screening visit, and at weeks 1, 6, 12, 24, 36, and 48.
|
Facial Clinimetric Evaluation Scale
Time Frame: From screening visit, and at weeks 6, 12, 24, 36, and 48.
|
FaCE is a patient questionnaire that measures the patient's perception of their facial movement, facial comfort, oral function, eye comfort, tear control, and social function.
Each one is scored separately to a total of 100, where 0 is the worst possible score to 100 is the best.
|
From screening visit, and at weeks 6, 12, 24, 36, and 48.
|
Patient Global Impression of Change
Time Frame: From screening visit, and at weeks 6, 12, 24, 36, and 48.
|
PGIC is a patient questionnaire that evaluates the patients perception of their overall health status.
A single-question with answers on a 7-point scale scored as: (1) "very much better," (2) "much better," (3) "a little better," (4) "no change," (5) "a little worse," (6) "much worse," or (7) "very much worse."
The following ranges demonstrate disease worsening (0-3 points), stable disease (4 points) or disease improvement (5-7 points) since the initial baseline or prior assessment.
|
From screening visit, and at weeks 6, 12, 24, 36, and 48.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Seth Schulman, MD, Chief Medical Officer
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTx21202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial Paralysis
-
Rebecka OhmRecruitingFacial Palsy | Bell Palsy | Facial Paralysis | Synkinesis | Peripheral Facial Palsy | Peripheral Facial ParalysisSweden
-
University of Campinas, BrazilCompletedPeripheral Facial ParalysisBrazil
-
Federal University of São PauloCompletedFacial Nerve Diseases | Orofacial Pain | Peripheral Nerve Facial Nerve ParalysisBrazil
-
Assistance Publique - Hôpitaux de ParisTerminatedUnilateral Peripheral Facial ParalysisFrance
-
Assiut UniversityUnknownFacial Nerve ParalysisEgypt
-
Peking Union Medical College HospitalRecruiting
-
Jaseng Medical FoundationRecruitingFacial Paralysis, PeripheralKorea, Republic of
-
Zhuan ZhangCompletedPeripheral Facial PalsyChina
-
University Hospital, CaenTerminatedFacial ParesisFrance
Clinical Trials on NTX-001
-
Major Extremity Trauma Research ConsortiumUnited States Department of DefenseRecruitingPeripheral Nerve InjuriesUnited States
-
Neuraptive Therapeutics Inc.Temporarily not availablePeripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial NervesUnited States
-
Neuraptive Therapeutics Inc.Active, not recruitingPeripheral Nerve InjuriesUnited States
-
University of Alabama at BirminghamRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaUnited States
-
Alkermes, Inc.Completed
-
Pinotbio, Inc.CompletedHealthy VolunteersKorea, Republic of
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina